Mobetron: The Surgical Alternative For More Patients With Pancreatic Cancer
Surgery isn’t an option for every patient diagnosed with pancreatic cancer. But with the IntraOp® Mobetron®, more patients than ever before are eligible. And we know that those who are treated surgically have a higher chance of survival. According to a recent publication from researchers at Mass General Hospital in the American Journal of Clinical Oncology. The use of IORT was “associated with encouraging median survival rates” with patients who underwent surgery and IORT experiencing a 43% increase in their median overall survival rate.
IntraOp Medical HQ
570 Del Rey Avenue
Sunnyvale, CA 94085